MIDAZOLAM INJECTION 5 MG
MIDAZOLAM : 5 MG · DIN 02240286 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is MIDAZOLAM INJECTION?
MIDAZOLAM INJECTION 5 MG contains MIDAZOLAM : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02240286, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 06-Oct-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MIDAZOLAM INJECTION used for?
IM premedication; IV sedation/anxiolysis/amnesia for short diagnostic/endoscopic procedures; induction of anesthesia; continuous IV infusion for sedation in ICU.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02240286 |
|---|---|
| Brand name | MIDAZOLAM INJECTION |
| Generic / active ingredient | MIDAZOLAM : 5 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 5 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; INTRAMUSCULAR |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05CD08 MIDAZOLAM |
| AHFS class | 28:24.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 06-Oct-2005 |
| Original market date | 1999-07-21 00:00:00 |
How is it administered?
Individualize dose. Administer slowly over 2-3 mins for sedation. IM: 0.07-0.08 mg/kg. IV Sedation: 1-2.5 mg initially. ICU: 0.01-0.03 mg/kg/hr infusion. Titrate to effect.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Stable for 24 hours when diluted to 0.03-0.5 mg/mL with 5% dextrose or 0.9% sodium chloride. (Specific temperature not in text).
How is it supplied?
Not explicitly detailed in provided text (mentions 1 mg/mL and 5 mg/mL formulations).
Contraindications
Hypersensitivity to benzodiazepines; acute pulmonary insufficiency; severe COPD; acute narrow angle glaucoma; intrathecal/epidural use; IV sedation in elderly/debilitated outside ICU.
Warnings and precautions
Serious cardiorespiratory events (respiratory depression/arrest); risk of addiction, abuse, misuse; withdrawal symptoms; risks from concomitant use with opioids.
Is MIDAZOLAM in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05CD08 MIDAZOLAM. 14 of 32 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BUCCOLAM | 10 MG / 2 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | DIN 02559609 |
| BUCCOLAM | 2.5 MG / 0.5 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | DIN 02559579 |
| BUCCOLAM | 5 MG / 1 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | DIN 02559587 |
| BUCCOLAM | 7.5 MG / 1.5 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | DIN 02559595 |
| MIDAZOLAM INJECTION | 1 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02240285 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02382377 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | STERINOVA INC. | MARKETED | DIN 02498022 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02382342 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02553104 |
| MIDAZOLAM INJECTION USP | 5 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02382385 |
Who else supplies MIDAZOLAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MIDAZOLAM appears in 146 registered pack listings across 14 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.